Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill could replace painful injections for deadly tropical disease

NCT ID NCT05957978

Summary

This study tested a new oral medicine called LXE408 against the standard treatment for visceral leishmaniasis, a serious parasitic infection. 52 adults in Ethiopia took either the new pill for 14 days or received standard injections for 17 days. Researchers compared how well each treatment worked and how safe they were, checking patients for up to 6 months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Gondar

    Gonder, Ethiopia

Conditions

Explore the condition pages connected to this study.